COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues
05/11/2025
Bagsværd, 5 November, 2025 - Financial report for the period 1 January 2025 to 30 September 2025 Operating profit increased by 5% in Danish kroner and 10% at constant exchange rates (CER) to DKK 95.9 billion, impacted [...]
LIfT BioSciences to present preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils at the 40th Society for Immunotherapy of Cancer
05/11/2025
London, 5 November 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces that preclinical data demonstrating the potential of [...]
AVEROA Receives UK MHRA Approval for XOANACYL®, an Oral Therapy Targeting Key Complications of Chronic Kidney Disease (CKD)
05/11/2025
The MHRA ( Medicines and Healthcare products Regulatory Agency) granted UK Marketing Authorisation for XOANACYL via the International Recognition Procedure (Route B) recognising its prior EU approval (June 2025) [...]
TME PHARMA POURSUIT SA NOUVELLE STRATÉGIE D'INVESTISSEMENT ET SIGNE UNE LETTRE D'INTENTION AVEC UNE SOCIÉTÉ ALLEMANDE SPÉCIALISÉE DANS LES RESSOURCES NATURELLES
05/11/2025
TME PHARMA POURSUIT SA NOUVELLE STRATÉGIE D'INVESTISSEMENT ET SIGNE UNE LETTRE D'INTENTION AVEC UNE SOCIÉTÉ ALLEMANDE SPÉCIALISÉE DANS LES RESSOURCES NATURELLES Nouvelle étape vers la diversification des investissements [...]
TME Pharma advances its new investment strategy and signs LOI with German resources company
05/11/2025
TME Pharma advances its new investment strategy and signs LOI with German resources company A further step toward investment diversification into potential cash-flow–generating assets A potential strategic investment in [...]
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
05/11/2025
COPENHAGEN, Denmark, November 5, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4.92% [...]
Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
05/11/2025
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the U.S. Food & Drug [...]
Pennant Acquires Senior Living Communities in Idaho and Wisconsin
05/11/2025
EAGLE, Idaho, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announces two [...]
HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®
05/11/2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces the completion of patient enrollment of SAFFRON, a [...]
RPX Enterprises and Xyngular Introduce XMD Wellness, a New Approach to Weight Loss and Wellness
05/11/2025
New clinician-guided program blends medical science, microdosing, and 24/7 support to make advanced weight loss and wellness accessible nationwide. XMD Wellness Logo MINERAL WELLS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE [...]
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
05/11/2025
Presentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for the treatment of obesity designed to drive fat loss while preserving muscle mass with once [...]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/11/2025
CHARLESTOWN, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]
Solana Company Files Application to Cease to Be a Reporting Issuer in Canada
04/11/2025
NEWTOWN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (“ Solana ” or the “ Company ”) today announced that it has applied to the British Columbia Securities Commission, as principal regulator, [...]
Prenetics Announces Third Quarter 2025 Financial Results Release Date and Inaugural Earnings Conference Call
04/11/2025
CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced it will release financial results for the [...]
Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update
04/11/2025
On track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease [...]
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
04/11/2025
Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea’s next-generation, oral small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA [...]
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/11/2025
MONTREAL and CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a [...]
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
04/11/2025
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and [...]
Revolution Medicines to Participate in November 2025 Investor Conferences
04/11/2025
REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]

Pages